Although at day 29, the AVID200+a-PD-1 combination resulted in a significantly decreased tumor size compared with isotype control and AVID200 alone, the combination was comparable to a-PD-1 monotherapy (Supplemental Figure 1A). The gene discussed is PDCD1; the disease is neoplasm.